Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen.

Rheumatology (Oxford) 2019 Feb 8. Epub 2019 Feb 8.

Division of Rheumatology, McGill University Health Centre, Montreal, Quebec, Canada.

Objectives: To assess the prevalence of combined hormonal contraceptives (CHCs) in reproductive-age women with SLE with and without possible contraindications and to determine factors associated with their use in the presence of possible contraindications.

Methods: This observational cohort study included premenopausal women ages 18-45 years enrolled in the SLICC Registry ⩽15 months after SLE onset, with annual assessments spanning 2000-2017. World Health Organization Category 3 or 4 contraindications to CHCs (e.g. hypertension, aPL) were assessed at each study visit. High disease activity (SLEDAI score >12 or use of >0.5 mg/kg/day of prednisone) was considered a relative contraindication.

Results: A total of 927 SLE women contributed 6315 visits, of which 3811 (60%) occurred in the presence of one or more possible contraindication to CHCs. Women used CHCs during 512 (8%) visits, of which 281 (55%) took place in the setting of one or more possible contraindication. The most frequently observed contraindications were aPL (52%), hypertension (34%) and migraine with aura (22%). Women with one or more contraindication were slightly less likely to be taking CHCs [7% of visits (95% CI 7, 8)] than women with no contraindications [9% (95% CI 8, 10)].

Conclusion: CHC use was low compared with general population estimates (>35%) and more than half of CHC users had at least one possible contraindication. Many yet unmeasured factors, including patient preferences, may have contributed to these observations. Further work should also aim to clarify outcomes associated with this exposure.

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/kez014DOI Listing
February 2019
14 Reads

Publication Analysis

Top Keywords

contraindication chcs
8
combined hormonal
8
hormonal contraceptives
8
women
7
contraindications
5
chcs
5
contraindication
4
presence contraindication
4
occurred presence
4
3811 60%
4
contributed 6315
4
6315 visits
4
visits 3811
4
chcs women
4
60% occurred
4
chcs 512
4
setting contraindication
4
contraindication frequently
4
frequently observed
4
place setting
4

References

(Supplied by CrossRef)
Contraceptive counseling and use among women with systemic lupus erythematosus: a gap in health care quality?
Yazdany et al.
Arthritis Care Res (Hoboken) 2011

WHO Scientific Group on Cardiovascular Disease and Steroid Hormone Contraception et al.
1997

World Health Organization et al.
2015

World Health Organization et al.
1996
U.S. selected practice recommendations for contraceptive use, 2016
Curtis et al.
MMWR Recomm Rep 2016
Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus
Somers et al.
J Rheumatol 2002

Similar Publications